This article published in Cell J (Yakhteh), Vol 20, No 2, Jul-Sep 2018, on pages 267-277, four affiliations (1, 4, 5, and 10)

were changed based on authors request

Abdolhosein Shahverdi

Ahmad Amin

Ahmad Vosough Dizaji

Ali Akhlaghi

Ali Bassi

Ali Hezavehei

Alireza Saadat

Azam Kouhkan

Davood Kazemi Saleh

Fahimeh Kashfi

Fattah Sotoodehnejadnematalahi

Gholamreza Bahoush

Hakimeh Sadeghian

Hamid Gourabi

Hoda Madani

Hossein Baharvand

Hossein Hosseinnejad

Leila Arab

Majid Dehghani

Mansour Movahhed

Maryam Esmaeilzadeh

Maryam Moshkani Farahani

Mehrnaz Namiri

Mohammad Hassan Naseri

Naeema Syedi

Narges Ramezanzadeh

Nasser Aghdami

Roghayeh Fazeli

Saeid Davaran

Saeid Hosseini

Sepideh Hekmat

Seyed Hossein Ahmadi Tafti

Seyedeh Esmat Hosseini

Soura Mardpour

Yaser Sharafi

Zargham Hossein Ahmadi

This article published in Cell J (Yakhteh), Vol 20, No 2, Jul-Sep 2018, on pages 267-277, four affiliations (1, 4, 5, and 10) were changed based on authors request. Â© 2018 Royan Institute (ACECR). All rights reserved

Naseri, M.H.

Madani, H.

Tafti, S.H.A.

Farahani, M.M.

Saleh, D.K.

Hosseinnejad, H.

Hosseini, S.

Hekmat, S.

Ahmadi, Z.H.

Dehghani, M.

Saadat, A.

Mardpour, S.

Hosseini, S.E.

Esmaeilzadeh, M.

Sadeghian, H.

Bahoush, G.

Bassi, A.

Amin, A.

Fazeli, R.

Sharafi, Y.

Arab, L.

Movahhed, M.

Davaran, S.

Ramezanzadeh, N.

Kouhkan, A.

Hezavehei, A.

Namiri, M.

Kashfi, F.

Akhlaghi, A.

Sotoodehnejadnematalahi, F.

Dizaji, A.V.

Gourabi, H.

Syedi, N.

Shahverdi, A.

Baharvand, H.

Aghdami, N.

eprints Iran University of Medical Sciences

 Cell J, Vol 20, No 3, Oct-Dec (Autumn) 2018 449CorrectionCOMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical TrialMohammad Hassan Naseri, M.D.1#, Hoda Madani, M.D.2#, Seyed Hossein Ahmadi Tafti, M.D.3, Maryam Moshkani Farahani, M.D.4, Davood Kazemi Saleh, M.D.5, Hossein Hosseinnejad, M.D.6, Saeid Hosseini, M.D.7, Sepideh Hekmat, M.D.8, Zargham Hossein Ahmadi, M.D.9, Majid Dehghani, M.D.6, Alireza Saadat, M.D.10, Soura Mardpour, M.Sc.2, Seyedeh Esmat Hosseini, M.Sc.2, 11, Maryam Esmaeilzadeh, M.D., FACC., FASE.12, Hakimeh Sadeghian, M.D.3, Gholamreza Bahoush, M.D.13, Ali Bassi, M.D.14, Ahmad Amin, M.D.15, Roghayeh Fazeli, M.D.2, Yaser Sharafi, M.D.10, Leila Arab, M.D.2, Mansour Movahhed, M.D.8, Saeid Davaran, M.D.3, Narges Ramezanzadeh, B.Sc.3, Azam Kouhkan, M.D.2, Ali Hezavehei, M.D.16, Mehrnaz Namiri, M.Sc.2, Fahimeh Kashfi, M.Sc.17, Ali Akhlaghi, M.Sc.17, Fattah Sotoodehnejadnematalahi, Ph.D.2, Ahmad Vosough Dizaji, M.D.18, Hamid Gourabi, Ph.D.19, Naeema Syedi, Ph.D.20, Abdolhosein Shahverdi, Ph.D.2, Hossein Baharvand, Ph.D.2, Nasser Aghdami, M.D., Ph.D.2*1. Department of Surgery, Baqiyatallah University of Medical Sceinces, Tehran, Iran2. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran3. Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran4. Department of Echocardiography, Baqiyatallah University of Medical Sceinces, Tehran, Iran5. Department of Cardiology, Baqiyatallah University of Medical Sceinces, Tehran, Iran6. Department of Cardiac Surgery, Lavasani Hospital, Social Security Organization, Tehran, Iran7. Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran8. Department of Nuclear Medicine, Hasheminejad Hospital, Tehran University of Medical Sciences, Tehran, Iran9. Transplantation Research Center, NRITLD, Masih Daneshvari Hospital, Shaheed Beheshti University of Medical Science, Darabad, Niavaran, Tehran, Iran10. Department of Internal Medicine, Baqiyatallah University of Medical Sceinces, Tehran, Iran11. Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran12. Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran13. Department of Pediatrics, Ali Asghar Pediatric Hospital, Tehran University of Medical Sciences, Tehran, Iran14. Department of Hematology and Oncology, Firoozgar Hospital, Iran University of Medical Sciences,Tehran, Iran15. Department of Heart Failure and Transplantation, Fellowship in Heart Failure and Transplantation, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran16. Department of Internal Medicine, Lavasani Hospital, Social Security Organization, Tehran, Iran17. Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran18. Department of Reproductive Imaging, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran19. Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran20. School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, South Australia, Australia*Corresponding Address: P.O.Box: 16635-148, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, IranEmail: Nasser.aghdami@royaninstitute.org#The first two authors equally contributed to this article.Citation: Naseri MH, Madani H, Ahmadi Tafti SH, Moshkani Farahani M, Kazemi Saleh D, Hosseinnejad H, Hosseini S, Hekmat S, Hossein Ahmadi Z, Dehghani M, Saadat A, Mardpour S, Hosseini SE, Esmaeilzadeh M, Sadeghian H, Bahoush Gh, Bassi A, Amin A, Fazeli R, Sharafi Y, Arab L, Movahhed M, Davaran S, Ramezanzadeh N, Kouhkan A, Hezavehei A, Namiri M, Kashfi F, Akhlaghi A, Sotoodehnejadnematalahi F, Vosough Dizaji A, Gourabi H, Syedi N, Shahverdi AH, Baharvand H, Aghdami N. COMPARE CPM-RMI trial: intramyocardial transplantation of autologous bone marrow-derived CD133+ cells and MNCs during CABG in patients with recent MI: a phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. Cell J. 2018; 20(3): 449. doi: 10.22074/cellj.2018.6018.This article published in Cell J (Yakhteh), Vol 20, No 2, Jul-Sep 2018, on pages 267-277, four affiliations (1, 4, 5, and 10) were changed based on authors request. 

Erratum: COMPARE CPM-RMI trial: Intramyocardial transplantation of autologous bone marrow-derived CD133+ cells and MNCs during CABG in patients with recent MI: A phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. (Cell Journal (2018) 20:3 (449) DOI: 10.22074/cellj.2018.5197)

Objective: The regenerative potential of bone marrow-derived mononuclear cells (MNCs) and CD133+ stem cells in the heart varies in terms of their pro-angiogenic effects. This phase II/III, multicenter and double-blind trial is designed to compare the functional effects of intramyocardial autologous transplantation of both cell types and placebo in patients with recent myocardial infarction (RMI) post-coronary artery bypass graft. Materials and Methods: This was a phase II/III, randomized, double-blind, placebo-controlled trial COMPARE CPM-RMI (CD133, Placebo, MNCs - recent myocardial infarction) conducted in accordance with the Declaration of Helsinki that assessed the safety and efficacy of CD133 and MNCs compared to placebo in patients with RMI. We randomly assigned 77 eligible RMI patients selected from 5 hospitals to receive CD133+ cells, MNC, or a placebo. Patients underwent gated single photon emission computed tomography assessments at 6 and 18 months post-intramyocardial transplantation. We tested the normally distributed efficacy outcomes with a mixed analysis of variance model that used the entire data set of baseline and between-group comparisons as well as within subject (time) and groupÃ�time interaction terms. Results: There were no related serious adverse events reported. The intramyocardial transplantation of both cell types increased left ventricular ejection fraction by 9 95% confidence intervals (CI): 2.14% to 15.78%, P=0.01 and improved decreased systolic wall thickening by -3.7 (95% CI: -7.07 to -0.42, P=0.03). The CD133 group showed significantly decreased non-viable segments by 75% (P=0.001) compared to the placebo and 60% (P=0.01) compared to the MNC group. We observed this improvement at both the 6- and 18-month time points. Conclusion: Intramyocardial injections of CD133+ cells or MNCs appeared to be safe and efficient with superiority of CD133+ cells for patients with RMI. Although the sample size precluded a definitive statement about clinical outcomes, these results have provided the basis for larger studies to confirm definitive evidence about the efficacy of these cell types (Registration Number: NCT01167751). Â© 2018 Royan Institute (ACECR). All Rights Reserved

COMPARE CPM-RMI Trial: Intramyocardial transplantation of autologous bone marrow-derived CD133+ Cells and MNCs during CABG in patients with recent MI: A Phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial

Directory of Open Access Journals